Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. develops AI-driven precision oncology therapies and research platforms for cancer drug discovery. The company uses its proprietary RADR® platform to identify and advance small-molecule oncology candidates, including LP-300, LP-184 and LP-284, and develops STAR-001 for CNS cancers through Starlight Therapeutics, its wholly owned subsidiary.
Recurring news includes clinical-program updates for lung cancer, hematologic cancers, sarcomas and brain cancers; FDA and trial-design communications; financial results; and commercialization of AI tools such as withZeta.ai and predictBBB.ai. Company updates also cover subscription-based platform access, computational biology features and enterprise deployment for biomedical research and drug-development users.
Summary not available.
Summary not available.
Summary not available.
Lantern Pharma (NASDAQ: LTRN) announced the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application related to its drug candidate LP-284, targeting non-Hodgkin's lymphomas. This patent is expected to provide market exclusivity until 2039. The company plans to submit an Investigational New Drug (IND) application for LP-284 to the FDA in mid-2023 and commence a Phase 1 clinical trial later this year. LP-284, with nanomolar potency, addresses significant unmet needs among patients with mantle cell lymphoma (MCL) and double-hit lymphoma (DHL), presenting an estimated annual market potential of $1.2 billion. The candidate has also received Orphan Drug Designation from the FDA for MCL, enhancing its development pathway.
Lantern Pharma Inc. (NASDAQ: LTRN) has initiated the Phase 2 Harmonic™ clinical trial, dosing the first patient with its investigational drug LP-300 in combination with chemotherapy for never smokers with advanced non-small cell lung cancer (NSCLC). The trial aims to assess the overall and progression-free survival in 90 patients, with 60 receiving LP-300 and 30 on standard chemotherapy. Previous trials showed a 91% overall survival rate at two years for LP-300 patients compared to those on chemotherapy alone. The market potential for this demographic is estimated between $1.5 to $2.0 billion.
Lantern Pharma Inc. (NASDAQ: LTRN), a biopharmaceutical company utilizing its RADR® AI platform for oncology drug development, announced presentations at three upcoming events. CEO Panna Sharma will present on March 22 at the Rare Disease Innovation & Partnership Summit in Philadelphia, discussing AI in drug development. He will also participate in a free webinar on March 23, co-hosted by Science History Institute and American Chemical Society, focusing on AI's impact on drug discovery. Additionally, Peter Carr will moderate a session at the Genomics in Precision Oncology Xchange on April 5 in Boston, emphasizing clinical trial design.
For more information, visit www.lanternpharma.com.
Lantern Pharma (NASDAQ: LTRN) announced significant operational highlights and financial results for the fourth quarter and fiscal year 2022. The Harmonic™ clinical trial for never-smoker patients with non-small cell lung cancer (NSCLC) has activated 5 clinical sites across 12 locations, with patient enrollment expected in Q2 2023. The company also completed IND-enabling studies for drug candidates LP-184 and LP-284, with IND submissions planned for April and mid-2023, respectively. Lantern reported a cash position of $55.2 million as of December 31, 2022, and expects a cash runway into 2025. The formation of Starlight Therapeutics for CNS cancer treatments was also highlighted.
Lantern Pharma Inc. (NASDAQ: LTRN) announced its participation in the AACR Annual Meeting from April 14-19, 2023 in Orlando, FL. The company will present a poster titled LP-184, an acylfulvene class small molecule therapeutic, focusing on its synthetic lethality mechanism targeting DNA damage repair deficient cancers, affecting 25-30% of solid tumors. The presentation is scheduled for April 19, 2023, 9:00 a.m. – 12:30 p.m. ET. Lantern aims to advance LP-184 to a Phase 1 clinical trial by mid-2023. Additionally, a webinar on synthetic lethality will be held on March 21, 2023 featuring expert Zoltan Szallasi.
Lantern Pharma Inc. (NASDAQ: LTRN) announced a webcast on March 20, 2023, at 4:30 p.m. ET, to disclose its fourth quarter and fiscal year 2022 financial results. Management, led by CEO Panna Sharma, will discuss operating and financial metrics for the fiscal year ended December 31, 2022 and outline upcoming milestones. Lantern Pharma is focused on oncology and leverages its proprietary RADR® AI platform to enhance drug discovery methods.
A replay will be available post-call on their investor relations website.
Lantern Pharma Inc. (NASDAQ: LTRN) announced that it has no exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank, ensuring its financial stability. The company’s cash, cash equivalents, and marketable securities are managed through top-tier financial institutions, providing sufficient resources to support operations and development through 2025. Lantern Pharma utilizes its proprietary RADR® AI platform to enhance oncology drug discovery, focusing on genomic profiling to identify patients likely to benefit from its therapeutics. This strategic approach aims to improve treatment outcomes for cancer patients.